The global launch has begun

We have initiated the commercialization of our product portfolio and aim to build a world-leading company in peri- and post-operative patient monitoring. Several agreements have been signed, and we are looking forward to our market launch.

Senzime develops products to meet healthcare demand for solutions that can reduce complications associated with surgery, increase patient safety and contribute to lower healthcare costs. As part of this effort, we concluded a new share issue in the first quarter of 2017 to provide growth capital and accelerate global commercialization of our product portfolio. In connection with this, we have completed a list change from the Share Market to Nasdaq First North during April.

We continue our journey to build a competitive patient monitoring company and our product portfolio is about to embark on a global market launch. The strategic acquisitions we made in 2015 and 2016 have strengthened our position and we now have several medical device lines that allow us to offer a more complete range of healthcare services.

Our unique system for reducing the severity of complications associated with residual neuromuscular block – TetraGraph – is in the final phase of the CE approval process. Although the new and increasingly complex regulations for medical technology have presented new challenges, we still expect CE approval to be achieved soon.

The cooperation with Japanese firm Fukuda Denshi, with which we signed an exclusive license agreement at the end of 2016, continues according to plan. The agreement means, among other things, that Fukuda will license and commercialize Senzime’s TetraGraph system on the Japanese market, with an expected launch date by the end of 2017. The agreement will last for 10 years and, according to Senzime’s management and board, will generate more than 100 MSEK in license revenue for Senzime. We consider this to be a breakthrough for Senzime.

The development work and the CE approval of OnZurf and CliniSenz continue, and here too, the plan is to shortly reach CE approvals and commence commercialization. As soon as CE approvals are in place, we will launch a broad market introduction in Europe of all three products as well as submit documentation to register the TetraGraph in both Japan and the United States.

We are looking forward to a continued eventful development in 2017 on the way to building a world-leading company in our fast-growing markets.

 

Uppsala, May 2017

 

Lena Söderström, CEO of Senzime AB (publ)